Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

Next Previous
X
Search
Trial Profile

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Abbott Laboratories; AbbVie; Genentech

    • Most Recent Events

    • 03 Jun 2021 Results (data cut off: 30 June 2020; n=106) assessing long-term follow-up from four cohorts (FL, MCL, WM, and MZL) of patients with relapsed or refractory non-Hodgkin lymphoma published in the Clinical Cancer Research
    • 04 Aug 2020 Data (n=435) from four phase 1 or 2 clinical trials (NCT01328626,NCT01682616, NCT01889186, NCT02141282) developing an integrated mechanistic model of kinetics of MRD in order to evaluate the impact of treatment duration on MRD published in the Clinical Pharmacology and Therapeutics
    • 15 May 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top